Development and Optimization of 111 In-Dinutuximab-IRDye800, a Dual-Modality Intraoperative Molecular Imaging Agent for Pediatric Neuroblastoma Resection
Authors:
- Catherine Y. YipCYCatherine Y. Yip
- Lauren T. RosenblumLRLauren T. Rosenblum
- Arjun PantAPArjun Pant
- Arianna Kahler-QuesadaAKArianna Kahler-Quesada
- Bhuvitha ChagantipatiBCBhuvitha Chagantipati
- ReidAnn SeverRSReidAnn Sever
- Brady Grano-MickelsenBGBrady Grano-Mickelsen
- Joseph D. LatocheJLJoseph D. Latoche
- Lora RigattiLRLora Rigatti
Preprint
Abstract
Rationale: Neuroblastoma is a devastating pediatric malignancy, for which surgical resection is a key factor in long-term survival. However, there are significant challenges in its resection, particularly in high-risk disease, as neuroblastoma encases surrounding critical structures, is often difficult to distinguish from desmoplastic or scar tissue, and can carry occult deposits of disease not readily identified on preoperative imaging or intraoperative visualization. Building on the principles of fluorescent and radio-guided surgery, in combination with the known overexpression of GD2 in neuroblastoma, we sought to develop and optimize 111 In-Dinutuximab-IRDye800, a dual-modality GD2-targeted intraoperative molecular imaging agent, for use in pediatric neuroblastoma to help enhance patient safety while facilitating a more complete resection. Methods: Dinutuximab was conjugated to IRDye800 and DTPA, then radiolabeled with Indium-111 to yield 111 In-Dinutuximab-IRDye800. Optimization occurred through ELISA assay to assess binding affinity, fluorescence intensity analysis to determine the optimal fluorescent degree of labeling, and phototoxicity testing through flow cytometry. Rodent models of neuroblastoma were then generated through injection of SK-N-BE(2) human neuroblastoma cells into the left adrenal glands of nude mice or RNU rats. A series of fluorescent and gamma biodistributions was performed, varying the dose, timing, and specific activity of the tracer. Tumor and organ uptake of the tracer was compared with one- or two-way ANOVA as appropriate, with Sidak’s multiple comparison test to compare tumor uptake to individual organs. Once optimization was complete, a clinically significant events study modeled after human clinical trials was performed to evaluate the in vivo capabilities of 111 In-Dinutuximab-IRDye800. Results: Increased ratios of IRDye800 per antibody led to decreased binding affinity for GD2 and was associated with formulation instability without significant return on fluorescence intensity. Specific activity of the tracer was not found to impact overall biodistribution of the tracer. A 45-50 µg dose of 111 In-Dinutuximab-IRDye800 with ratios around 1 DTPA and 1-1.5 IRDye800 per antibody imaged 4 days after tracer administration was found to be the optimal combination that maximized detectable tumor-specific signal. In the clinically significant events study mirroring human IMI clinical trials, fluorescent guidance identified additional malignant lesions not originally detected under white light in 64% of rodents. Conclusions: 111 In-Dinutuximab-IRDye800 is a dual-modality GD2-targeted intraoperative imaging agent that is well-poised for clinical translation. As it preserves tumor specificity, yields clinically meaningful radiofluorescent signal, and is well-tolerated without adverse events after optimization was completed, it carries the potential to positively impact the safety and completeness of neuroblastoma resection.Keywords
Funding Information
- RK Mellon Foundation Mellon Scholar Award
- Marjory K. Harmer Endowment for Research in Pediatric Pathology
- NCI of the NIH (T32CA113263)
- NCI of the NIH (F32CA287961)
- NCI of the NIH (R01 CA277664)
- NIH P30 (CA047904)
- NIH P30 (PAR-20-043)
This publication has 37 references indexed in Scilit:
- Global, regional, and national epidemiology of childhood neuroblastoma (1990–2021): a statistical analysis of incidence, mortality, and DALYseClinicalMedicine, 2024
- Lessons learned in application driven imaging agent design for image-guided surgeryEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trialThe Journal of Thoracic and Cardiovascular Surgery, 2023
- 99mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate CancerEuropean Urology, 2019
- Neuroblastoma patient‐derived orthotopic xenografts retain metastatic patterns and geno‐ and phenotypes of patient tumoursInternational Journal of Cancer, 2014
- Production and separation of 111In: an important radionuclide in life sciences: a mini reviewJournal of Radioanalytical and Nuclear Chemistry, 2012
- Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysisBreast Cancer Research and Treatment, 2011
- NeuroblastomaThe Lancet, 2007
- Surgical treatment for neuroblastoma: Complications during 15 years' experienceJournal of Pediatric Surgery, 1998
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992